美国 · SEC FORM 4
GYRE THERAPEUTICS, INC.
GYRE · Nasdaq · CIK 0001124105 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
34 同一窗口内观察到的 Form 4 交易行
18 sales · 16 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2022-08-09 · USMAN NASSIM.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 1,918,512
- 上期报告
- 1,730,215
- 日均成交量
- 277,117
- 回补天数
- 6.9
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2022-08-09 | USMAN NASSIM | 买入 (P) | Common Stock | 3,250 | USD 0.47 | USD 1,528 | SEC 申报 ↗ |
| 2022-08-09 | Miller Seline E. | 买入 (P) | Common Stock | 3,250 | USD 0.47 | USD 1,528 | SEC 申报 ↗ |
| 2022-08-09 | Blouse Grant E. | 买入 (P) | Common Stock | 3,250 | USD 0.47 | USD 1,528 | SEC 申报 ↗ |
| 2022-02-09 | USMAN NASSIM | 买入 (P) | Common Stock | 3,250 | USD 0.46 | USD 1,495 | SEC 申报 ↗ |
| 2022-02-09 | Miller Seline E. | 买入 (P) | Common Stock | 3,250 | USD 0.46 | USD 1,495 | SEC 申报 ↗ |
| 2022-02-09 | Blouse Grant E. | 买入 (P) | Common Stock | 3,250 | USD 0.46 | USD 1,495 | SEC 申报 ↗ |
| 2021-08-09 | USMAN NASSIM | 买入 (P) | Common Stock | 867 | USD 3.62 | USD 3,139 | SEC 申报 ↗ |
| 2021-08-09 | Levy Howard | 买入 (P) | Common Stock | 639 | USD 3.62 | USD 2,313 | SEC 申报 ↗ |
| 2021-08-09 | Blouse Grant E. | 买入 (P) | Common Stock | 1,163 | USD 3.62 | USD 4,210 | SEC 申报 ↗ |
| 2021-02-09 | USMAN NASSIM | 买入 (P) | Common Stock | 582 | USD 4.81 | USD 2,799 | SEC 申报 ↗ |
| 2021-02-09 | Levy Howard | 买入 (P) | Common Stock | 1,670 | USD 4.81 | USD 8,033 | SEC 申报 ↗ |
| 2020-08-10 | USMAN NASSIM | 买入 (P) | Common Stock | 582 | USD 4.81 | USD 2,799 | SEC 申报 ↗ |
| 2020-08-10 | Levy Howard | 买入 (P) | Common Stock | 1,768 | USD 4.81 | USD 8,504 | SEC 申报 ↗ |
| 2020-03-16 | Levy Howard | 买入 (P) | Common Stock | 2,500 | USD 4.05 | USD 10,125 | SEC 申报 ↗ |
| 2020-03-13 | USMAN NASSIM | 买入 (P) | Common Stock | 4,000 | USD 3.91 | USD 15,640 | SEC 申报 ↗ |
Form 4 申报证据
34 transaction lines in the latest 365-day window; 215 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Ye Weiguo | 卖出 (S) | Common Stock | 3,000 | USD 6.35 | USD 19,050 | SEC 申报 ↗ |
| 2026-06-18 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 3,000 | USD 0.75 | USD 2,250 | SEC 申报 ↗ |
| 2026-06-11 | Ye Weiguo | 卖出 (S) | Common Stock | 2,800 | USD 6.17 | USD 17,276 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Ye Weiguo | 卖出 (S) | Common Stock | 3,000 | USD 6.35 | USD 19,050 | SEC 申报 ↗ |
| 2026-06-18 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 3,000 | USD 0.75 | USD 2,250 | SEC 申报 ↗ |
| 2026-06-11 | Ye Weiguo | 卖出 (S) | Common Stock | 2,800 | USD 6.17 | USD 17,276 | SEC 申报 ↗ |
| 2026-06-11 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 2,800 | USD 0.75 | USD 2,100 | SEC 申报 ↗ |
| 2026-06-10 | Ye Weiguo | 卖出 (S) | Common Stock | 5,000 | USD 6.24 | USD 31,200 | SEC 申报 ↗ |
| 2026-06-10 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 5,000 | USD 0.75 | USD 3,750 | SEC 申报 ↗ |
| 2026-06-10 | Ye Weiguo | 卖出 (S) | Common Stock | 6,418 | USD 6.21 | USD 39,856 | SEC 申报 ↗ |
| 2026-06-10 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 6,418 | USD 0.75 | USD 4,814 | SEC 申报 ↗ |
| 2026-06-09 | Ye Weiguo | 卖出 (S) | Common Stock | 3,000 | USD 6.15 | USD 18,450 | SEC 申报 ↗ |
| 2026-06-09 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 3,000 | USD 0.75 | USD 2,250 | SEC 申报 ↗ |
| 2026-06-09 | Ye Weiguo | 卖出 (S) | Common Stock | 14,500 | USD 6.14 | USD 89,030 | SEC 申报 ↗ |
| 2026-06-09 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 14,500 | USD 0.75 | USD 10,875 | SEC 申报 ↗ |
| 2026-06-05 | Ye Weiguo | 卖出 (S) | Common Stock | 15,401 | USD 6.40 | USD 98,566 | SEC 申报 ↗ |
| 2026-06-05 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 15,401 | USD 0.75 | USD 11,551 | SEC 申报 ↗ |
| 2026-06-04 | Ye Weiguo | 卖出 (S) | Common Stock | 19,575 | USD 6.13 | USD 119,995 | SEC 申报 ↗ |
| 2026-06-04 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 19,575 | USD 0.75 | USD 14,681 | SEC 申报 ↗ |
| 2026-05-26 | Ye Weiguo | 卖出 (S) | Common Stock | 4,000 | USD 6.10 | USD 24,400 | SEC 申报 ↗ |
| 2026-05-26 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 4,000 | USD 0.75 | USD 3,000 | SEC 申报 ↗ |
| 2026-05-22 | Ye Weiguo | 卖出 (S) | Common Stock | 3,500 | USD 6.08 | USD 21,280 | SEC 申报 ↗ |
| 2026-05-22 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 3,500 | USD 0.75 | USD 2,625 | SEC 申报 ↗ |
| 2026-05-21 | Ye Weiguo | 卖出 (S) | Common Stock | 12,820 | USD 6.15 | USD 78,843 | SEC 申报 ↗ |
| 2026-05-21 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 12,820 | USD 0.75 | USD 9,615 | SEC 申报 ↗ |
| 2026-05-20 | Ye Weiguo | 卖出 (S) | Common Stock | 9,400 | USD 6.15 | USD 57,810 | SEC 申报 ↗ |
| 2026-05-20 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 9,400 | USD 0.75 | USD 7,050 | SEC 申报 ↗ |
| 2026-05-19 | Ye Weiguo | 卖出 (S) | Common Stock | 9,120 | USD 6.37 | USD 58,094 | SEC 申报 ↗ |
| 2026-05-19 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 9,120 | USD 0.75 | USD 6,840 | SEC 申报 ↗ |
| 2026-05-18 | Ye Weiguo | 卖出 (S) | Common Stock | 200 | USD 6.62 | USD 1,324 | SEC 申报 ↗ |
| 2026-05-18 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 200 | USD 0.75 | USD 150 | SEC 申报 ↗ |
| 2026-05-15 | Ye Weiguo | 卖出 (S) | Common Stock | 13,100 | USD 6.65 | USD 87,115 | SEC 申报 ↗ |
| 2026-05-15 | Ye Weiguo | 期权行权/转换 (M) | Common Stock | 13,100 | USD 0.75 | USD 9,825 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | GYRE |
| CIK | 0001124105 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 215 transaction lines from 2020-01-02 to 2026-06-18 19 P purchase lines · 111 S sale lines · 85 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.